Table 1.
Demographic and clinical characteristics of the study population.
| Characteristic | Compression device | Control (n = 102) | P-value |
|---|---|---|---|
| Demographics | |||
| Age, mean ± SD, y | 73.5 ± 7.4 | 71.1 ± 7.2 | 0.04 |
| Male, n (%) | 66 (64.7) | 63 (61.8) | 0.36 |
| BMI, mean ± SD, kg/m2 | 23.8 ± 3.1 | 23.6 ± 3.0 | 0.77 |
| CHA2DS2-VASc score | 3.7 ± 1.3 | 3.6 ± 1.3 | 0.86 |
| Comorbid condition, n (%) | |||
| Hypertension | 59 (57.8) | 63 (61.8) | 0.47 |
| Diabetes | 32 (31.4) | 33 (32.4) | 0.72 |
| Coronary heart disease | 30 (29.4) | 32 (31.4) | 0.69 |
| Heart failure | 32 (31.4) | 32 (31.4) | 0.99 |
| Sinus node dysfunction | 36 (35.3) | 33 (32.3) | 0.62 |
| Atrioventricular block | 47 (46.1) | 48 (47.1) | 0.86 |
| Laboratory parameters, mean ±SD | |||
| PT, s | 23.5 ± 1.3 | 23.8 ± 1.4 | 0.63 |
| APTT, s | 40.9 ± 2.8 | 41.2 ± 2.9 | 0.33 |
| Creatinine, umol/L | 74.2 ± 13.6 | 73.6 ± 13.3 | 0.45 |
| Hemoglobin, g/L | 126.2 ± 8.5 | 128.2 ± 8.7 | 0.23 |
| Platelet count, 10∧9/L | 202 ± 55 | 210 ± 58 | 0.12 |
| LVEF, % | 40 ± 12 | 41 ± 12 | 0.86 |
| Direct oral anticoagulant, n (%) | |||
| Dabigatran | 42 (41.2) | 44 (43.1) | 0.65 |
| Rivaroxaban | 60 (58.8) | 58 (56.9) | 0.63 |
| Concomitant antiplatelet | |||
| medication, n (%) | |||
| Aspirin | 24 (23.5) | 20 (19.6) | 0.33 |
| Clopidogrel | 16 (15.7) | 18 (17.6) | 0.42 |
| Type of device, n (%) | |||
| Pacermaker | 59 (57.8) | 58 (56.9) | 0.69 |
| Implantable cardioverter defibrillator | 7 (6.9) | 8 (7.8) | 0.52 |
| CRT and CRT-D | 10 (9.8) | 11 (10.8) | 0.77 |
| Generator exchange | 26 (25.5) | 25 (24.5) | 0.54 |
| Operation duration, mean ± SD, min | 82.2 ± 33.5 | 85.2 ± 37.0 | 0.23 |
SD, standard deviation; PT, prothrombin time; APTT, activated partial thromboplastin time; LEVF, left ventricular ejection fraction; CRT, cardiac resynchronization therapy; CRT-D, defibrillator cardiac resynchronization therapy.